StreetInsider.com News Articles

Form 3 JUPITER NEUROSCIENCES, For: Jul 22 Filed by: Cutler Andrew Jon

Wed, 22 Jul 2026 21:13:00 -0400

si-local-file:///var/storage/secattach/20260722/26803000.html

Form 3 JUPITER NEUROSCIENCES, For: Jul 22 Filed by: Cutler Andrew Jon

Wed, 22 Jul 2026 21:13:00 -0400

si-local-file:///var/storage/secattach/20260722/26803000.html

Form 424B3 JUPITER NEUROSCIENCES,

Tue, 21 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260721/26795646.html

Form 424B3 JUPITER NEUROSCIENCES,

Tue, 21 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260721/26795646.html

Form 8-K JUPITER NEUROSCIENCES, For: Jul 20

Tue, 21 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26795604.html

Form 8-K JUPITER NEUROSCIENCES, For: Jul 20

Tue, 21 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26795604.html

Jupiter Neurosciences licenses MDMA-based drug ALA-002 for up to $100M

Tue, 21 Jul 2026 07:13:13 -0400

Jupiter Neurosciences (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented non-racemic MDMA formulation, in a deal valued at up to $100 million including milestone payments.

The upfront payment totals $3.3 million, comprising $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. Additional payments include $3.3 million upon Phase 3 first patient enrollment, $20 million upon U.S. NDA approval, and commercial milestones of $10 million, $30 million, and $33.3 million tied to cumulative U.S. net sales of $333 million, $1 billion,

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Tue, 21 Jul 2026 07:13:00 -0400

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program

JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Tue, 21 Jul 2026 07:13:00 -0400

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Tue, 21 Jul 2026 07:13:00 -0400

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Tue, 21 Jul 2026 07:13:00 -0400

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program

PharmAla licenses U.S. rights to ALA-002 to Jupiter Neurosciences

Tue, 21 Jul 2026 07:00:14 -0400

PharmAla Biotech Holdings Inc. (CSE: MDMA, OTCQB: MDXXF) signed a definitive license agreement on July 20, 2026, granting Jupiter Neurosciences, Inc. (NASDAQ: JUNS) exclusive, perpetual rights to develop, manufacture, and commercialize ALA-002 in the United States.

The total consideration payable to PharmAla under the agreement is up to approximately $100 million. This includes a $3,333,333 upfront payment — comprised of $1,500,000 in cash and $1,833,333 in Jupiter common stock subject to a 120-day lock-up — and up to $96,666,666 in contingent milestone payments tied to development, regulatory, and sales targets.

Development and regulatory milestones total up to $23,333,333, including $3,333,333 upon first

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

Tue, 21 Jul 2026 07:00:00 -0400

TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has entered into a definitive license agreement (the “Agreement”) on July 20^th, 2026 with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter”), under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla’s lead drug candidate, in the United States. PharmAla retains all rights to ALA-002 outside the

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

Tue, 21 Jul 2026 07:00:00 -0400

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

Tue, 21 Jul 2026 07:00:00 -0400

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

Tue, 21 Jul 2026 07:00:00 -0400

Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Rosen Alexander Gustaf Erik

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762391.html

Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Rosen Alexander Gustaf Erik

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762391.html

Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Kampf Julie B.

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762393.html

Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Kampf Julie B.

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762393.html

Form 4 JUPITER NEUROSCIENCES, For: Jun 02 Filed by: Hemmerly Nicholas H.